IMMUNITYBIO, INC. Capital Expenditures Incurred but Not yet Paid
IMMUNITYBIO, INC. (IBRX) reported Capital Expenditures Incurred but Not yet Paid of $2.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-04
- IMMUNITYBIO, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was $976.00K, a 395.43% increase year-over-year.
- IMMUNITYBIO, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $1.41M, a 27.01% increase year-over-year.
- IMMUNITYBIO, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $792.00K.
- IMMUNITYBIO, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$741.00K.
- IMMUNITYBIO, INC. capital expenditures incurred but not yet paid for fiscal 2025 was $1.35M, a 81.15% increase from fiscal 2024.
- IMMUNITYBIO, INC. capital expenditures incurred but not yet paid for fiscal 2024 was $748.00K, a 35.29% decline from fiscal 2023.
- IMMUNITYBIO, INC. capital expenditures incurred but not yet paid for fiscal 2023 was $1.16M, a 90.89% decline from fiscal 2022.
- IMMUNITYBIO, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $12.69M, a 8.92% increase from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 3 month as first filed | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 6 month as first filed | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 9 month as first filed | Capital Expenditures Incurred but Not yet Paid 12 month | Capital Expenditures Incurred but Not yet Paid 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $976.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $2.38M 10-Q · filed 2026-08-04 | $3.17M derived: sum of 3 quarters · filed 2026-08-04 | $2.43M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $1.41M 10-Q · filed 2026-05-07 | $2.20M derived: sum of 2 quarters · filed 2026-05-07 | $1.46M derived: sum of 3 quarters · filed 2026-05-07 | $1.65M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $792.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $51.00K derived: sum of 2 quarters · filed 2026-02-23 | $248.00K derived: sum of 3 quarters · filed 2026-08-04 | $1.35M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | -$741.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$544.00K derived: sum of 2 quarters · filed 2026-08-04 | $563.00K 10-Q · filed 2025-11-05 | -$52.00K derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $197.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.30M 10-Q · filed 2026-08-04 | $689.00K derived: sum of 3 quarters · filed 2026-08-04 | -$943.00K derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $1.11M 10-Q · filed 2026-05-07 | $492.00K derived: sum of 2 quarters · filed 2026-05-07 | -$1.14M derived: sum of 3 quarters · filed 2026-05-07 | $476.00K derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$615.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$2.25M derived: sum of 2 quarters · filed 2026-02-23 | -$631.00K derived: sum of 3 quarters · filed 2026-02-23 | $748.00K 10-K · filed 2026-02-23 | ||||
| 2024-09-30 | -$1.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$16.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.36M 10-Q · filed 2025-11-05 | -$8.38M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-06-30 | $1.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $3.00M 10-Q · filed 2025-08-05 | -$6.75M derived: sum of 3 quarters · filed 2026-02-23 | -$7.84M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-03-31 | $1.38M 10-Q · filed 2025-05-12 | -$8.37M derived: sum of 2 quarters · filed 2026-02-23 | -$9.46M derived: sum of 3 quarters · filed 2026-02-23 | -$16.50M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2023-12-31 | -$9.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$10.84M derived: sum of 2 quarters · filed 2026-02-23 | -$17.88M derived: sum of 3 quarters · filed 2026-02-23 | $1.16M 10-K · filed 2026-02-23 | ||||
| 2023-09-30 | -$1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$8.13M derived: sum of 2 quarters · filed 2024-11-12 | $10.90M 10-Q · filed 2024-11-12 | $11.13M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-06-30 | -$7.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $11.99M 10-Q · filed 2024-08-12 | $12.22M derived: sum of 3 quarters · filed 2025-03-03 | $11.23M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-03-31 | $19.03M 10-Q · filed 2024-05-09 | $19.26M derived: sum of 2 quarters · filed 2025-03-03 | $18.27M derived: sum of 3 quarters · filed 2025-03-03 | $30.66M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2022-12-31 | $224.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$761.00K derived: sum of 2 quarters · filed 2025-03-03 | $11.63M derived: sum of 3 quarters · filed 2025-03-03 | $12.69M 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | -$985.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $11.41M derived: sum of 2 quarters · filed 2023-11-09 | $12.47M 10-Q · filed 2023-11-09 | $18.54M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-06-30 | $12.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $13.45M 10-Q · filed 2023-08-08 | $19.53M derived: sum of 3 quarters · filed 2024-03-19 | $16.76M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-03-31 | $1.06M 10-Q · filed 2023-05-11 | $7.13M derived: sum of 2 quarters · filed 2024-03-19 | $4.37M derived: sum of 3 quarters · filed 2024-03-19 | $8.45M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2021-12-31 | $6.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $3.31M derived: sum of 2 quarters · filed 2024-03-19 | $7.39M derived: sum of 3 quarters · filed 2024-03-19 | $11.65M 10-K · filed 2024-03-19 | ||||
| 2021-09-30 | -$2.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.31M derived: sum of 2 quarters · filed 2022-11-09 | $5.58M 10-Q · filed 2022-11-09 | $5.28M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | $4.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $8.35M 10-Q · filed 2022-08-08 | $8.04M derived: sum of 3 quarters · filed 2023-03-01 | $6.20M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | $4.27M 10-Q · filed 2022-05-10 | $3.96M derived: sum of 2 quarters · filed 2023-03-01 | $2.12M derived: sum of 3 quarters · filed 2023-03-01 | $4.12M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | -$304.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$2.15M derived: sum of 2 quarters · filed 2023-03-01 | -$147.00K derived: sum of 3 quarters · filed 2023-03-01 | $220.00K 10-K · filed 2023-03-01 | $289.00K 10-K · filed 2021-03-04 | |||
| 2020-09-30 | -$1.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $157.00K derived: sum of 2 quarters · filed 2021-11-12 | $524.00K 10-Q · filed 2021-11-12 | $339.00K 10-Q · filed 2020-11-09 | $998.00K derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $2.37M 10-Q · filed 2021-08-12 | $2.13M 10-Q · filed 2020-08-07 | $2.84M derived: sum of 3 quarters · filed 2022-03-01 | $1.72M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-03-31 | $367.00K 10-Q · filed 2021-05-14 | $182.00K 10-Q · filed 2020-05-11 | $841.00K derived: sum of 2 quarters · filed 2022-03-01 | -$279.00K derived: sum of 3 quarters · filed 2022-03-01 | -$1.00M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $474.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$646.00K derived: sum of 2 quarters · filed 2022-03-01 | -$1.37M derived: sum of 3 quarters · filed 2022-03-01 | $662.00K 10-K · filed 2022-03-01 | $74.00K 10-K · filed 2020-03-25 | |||
| 2019-09-30 | -$1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$1.84M derived: sum of 2 quarters · filed 2020-11-09 | $188.00K 10-Q · filed 2020-11-09 | $415.00K derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-06-30 | -$723.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $1.31M 10-Q · filed 2020-08-07 | $1.53M derived: sum of 3 quarters · filed 2021-03-04 | -$732.00K derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-03-31 | $2.03M 10-Q · filed 2020-05-11 | $2.26M derived: sum of 2 quarters · filed 2021-03-04 | -$9.00K derived: sum of 3 quarters · filed 2021-03-04 | |||||
| 2018-12-31 | $227.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$2.04M derived: sum of 2 quarters · filed 2021-03-04 | $4.66M 10-K · filed 2021-03-04 | |||||
| 2018-09-30 | -$2.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $4.44M 10-Q · filed 2019-11-05 | ||||||
| 2018-06-30 | $6.70M 10-Q · filed 2019-08-06 | |||||||
| 2017-12-31 | $9.50M 10-K · filed 2020-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |